The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The index has shown a price loss of -22.31% this year. Over the last six months, there has been a stronger performance of -28.93%. The price of ZNTL leaped by -13.33% during the last 30 days period. For the last 5-days stocks have slided -7.40%.
Zentalis Pharmaceuticals Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $31.46 on 05/30/23, while the lowest price for the same period was registered at $9.56 on 11/08/23.
52-week price history of ZNTL Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Zentalis Pharmaceuticals Inc’s current trading price is -62.59% away from its 52-week high, while its distance from the 52-week low is 23.12%. The stock’s price range during this time has been between $9.56 and $31.46. The trading volume for the Healthcare sector company’s shares reached about 0.76 million for the day, which was lower than the average daily volume of 0.82 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -10.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 835.20M and boasts a workforce of 168 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 13.74, with a change in price of +1.16. Similarly, Zentalis Pharmaceuticals Inc recorded 845,665 in trading volume during the last 100 days, posting a change of +10.93%.
ZNTL’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.10.
ZNTL Stock Stochastic Average
Today, Zentalis Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 16.00%, indicating a rise from the raw stochastic average of the last 20 days, which was 3.02%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 9.16% and 11.55% respectively.
